Skip to main content
Fig. 8 | BMC Medical Ethics

Fig. 8

From: Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development

Fig. 8

Pharmacist-reported support for the use of vaccine-based therapy across various clinical scenarios (a, b) and populations (c, d), under voluntary-use (a, c) and mandatory-use (b, d) scenarios. The dotted line on the figures indicates a true neutral response. All data plotted as mean ± SEM. ****p < 0.0001 vs. voluntary use in populations at-risk for OUD; ###p < 0.001 vs. voluntary use in populations with an OUD diagnosis with ongoing use;^^p < 0.01 vs. voluntary use in populations post-opioid overdose;++p < 0.01 vs. voluntary use in populations in drug court for opioid-related offences; $$$$p < 0.0001 vs. voluntary in-recovery; %%%p < 0.001 vs. voluntary use in children; >>>p < 0.001 vs. voluntary use in pregnant individuals; <<<p < 0.001 vs. voluntary use in prisoners

Back to article page